PHLDA1 Mediates Drug Resistance in Receptor Tyrosine Kinase-Driven Cancer.

ABSTRACT: Development of resistance causes failure of drugs targeting receptor tyrosine kinase (RTK) networks and represents a critical challenge for precision medicine. Here, we show that PHLDA1 downregulation is critical to acquisition and maintenance of drug resistance in RTK-driven cancer. Using fibroblast growth factor receptor (FGFR) inhibition in endometrial cancer cells, we identify an Akt-driven compensatory mechanism underpinned by downregulation of PHLDA1. We demonstrate broad clinical relevance of our findings, showing that PHLDA1 downregulation also occurs in response to RTK-targeted therapy in breast and renal cancer patients, as well as following trastuzumab treatment in HER2⁺ breast cancer cells. Crucially, knockdown of PHLDA1 alone was sufficient to confer de novo resista

SUBMITTER: Fearon AE 

PROVIDER: S-EPMC5848852 | biostudies-literature | 2018 Feb

REPOSITORIES: biostudies-literature